Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in January 2011 on request of the sponsor.
On 29 November 2007, orphan designation (EU/3/07/512) was granted by the European Commission to MedImmune Oncology, Inc., Netherlands, for 17-(allylamino)-17-demethoxygeldanamycin hydroquinone hydrochloride for the treatment of malignant gastrointestinal stromal tumours.
The sponsorship was transferred to AstraZeneca AB, Sweden, in June 2008 and subsequently to Voising Consulting S.A.R.L., France, in April 2009.
EU/3/07/512: Public summary of positive opinion for orphan designation of 17-(allylamino)-17-demethoxygeldanamycin hydroquinone hydrochloride for the treatment of malignant gastrointestinal stromal tumours (PDF/124.2 KB)
First published: 17/09/2009
Last updated: 25/03/2011
17-(Allylamino)-17-demethoxygeldanamycin, hydroquinone hydrochloride
|Disease / condition||
Treatment of malignant gastrointestinal stromal tumours
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.